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ABSTRACT 
Acute lung injury (ALI) is a form of acute respiratory failure, having an estimated 
annual incidence of 200,000 with a 40% mortality rate in the United States alone. 
Patients suffering from hemolytic diseases such as sepsis, malaria, and sickle cell 
disease are placed at a greater risk of developing ALI because of the excess amount of 
heme release that occurs during the pathogenesis of these diseases. Free heme is 
known to be a danger associated molecular pattern (DAMP) molecule and previous 
reports from our lab have identified particularly toxic effects apply to the lung endothelial 
barrier, ultimately contributing to ALI. However, the cellular mechanism of how heme is 
able to cause endothelial damage remains largely unknown. Recent studies have 
revealed that heme is able to induce the activation of nod-like receptor 3 (NLRP3) 
inflammasome in monocytes, which is followed by the maturation and release of 
inflammatory molecules Interleukin-1β (IL-1β) and Interleukin-18 (IL-18). Therefore, in 
this study we hypothesized that heme induces NLRP3 in pulmonary microvascular 
endothelial cells, resulting in destructive inflammatory activity that leads to the 
development of ALI. To test this hypothesis, we challenged human primary 
microvascular endothelial cells (HMVEC-Ls) with heme and assessed cell death, barrier 
integrity, cytokine release, and NLRP3 activation. Heme challenge of HMVEC-Ls 
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produced a 75% decrease in barrier resistance as compared to vehicle, measured via 
electrical cell-substrate impedance sensing (ECIS). This barrier instability was 
concomitant with a significant 3-fold increase in IL-18 (p=0.046) release and an increase 
in NLRP3 protein, measured through extracellular supernatant and western blot 
respectively. Importantly, inhibition of NLRP3 resulted in a 35% increase in barrier 
integrity, which corresponded to a 20% decrease in lung wet-to-dry weight ratio in mice 
that were injected with heme. These results demonstrate that heme mediated 
endothelial damage involves an inflammatory response associated with NLRP3 
activation, which is a potential target for therapeutic intervention. Future studies are 
warranted to confirm heme-mediated inflammasome formation and activation. 
Identifying specific molecular and cellular mechanisms by which heme damages the 
vascular endothelium in the pathogenesis of ALI is important for decreasing morbidity 
among patients and improving the overall health of the public.  
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1.0  INTRODUCTION 
1.1 EPIDEMIOLOGY 
Acute lung injury (ALI) is a form of respiratory failure with an estimated annual 
incidence of 200,000 and a devastating mortality rate of 40% in the United States alone. 
Several conditions resulting from disease or physical trauma may predispose certain 
patients to develop ALI, while factors such as age and race have been implicated in 
affecting overall mortality. For example, it is established that younger patients are more 
resilient, and therefore survive ALI at a much higher rate than their older counterparts. In 
addition, racial inequalities are shown to result in higher 60-day mortality rates among 
African-Americans and Hispanics as compared to Caucasians (1-4). Predisposing 
conditions or clinical factors for the development of ALI include sepsis, trauma, blood 
transfusions, smoke or gas inhalation, sickle cell disease (SCD), pneumonia, and 
pancreatitis (5-9). 
Over the past two decades there has been an apparent downward trend in mortality 
associated with ALI (10, 11). However, this trend should be received with caution as a 
precise clinical definition for ALI was only recently reached in 1994. Prior to this, the 
diagnosis criteria varied greatly, making the epidemiologic assessment of ALI incidence 
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extremely challenging. According to the American-European Consensus Conference 
Committee, the official definition of ALI occurs in a patient that meets the flowing criteria: 
• arterial oxygen partial pressure to fractional inspired oxygen ratio
(PaO2/FiO2) ≤ 300
• chest radiograph of acute onset bilateral pulmonary infiltration
• absence of left atrial hypertension (12).
The definition has become widely used because of its simplicity and effectiveness in 
quantifying the overall severity of lung injury (4, 13), however the objective approach that 
is required in order to quantify chest radiographs has been called in to question, potentially 
indicating the need for a revision (14, 15).  
1.2 PATHOGENESIS 
In general, the pathogenesis of ALI is caused by the acute agitation of the 
alveolar-capillary membrane. The alveolar-capillary membrane, as depicted in figure 1, 
involves the microvascular endothelial cells, which line the blood vessels of the lung, 
and the alveolar epithelial cells which line the alveolar sacs of the lung. The alveolar 
epithelial cells are further divided into two types: type I and type II. The vast majority of 
the alveolar surface area is composed of fragile type I cells, leaving only about 10 
percent of total area for the more resistant type II cells. Type II cells are also 
responsible for surfactant production, ion transportation, and epithelial cell repair. Under 
normal physiological circumstances, shown on the left of figure 1, endothelial cells form 
a tight barrier, disallowing the circulating cells from passing through into the interstitial 
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space, while healthy alveoli are free of excess fluid and contain only inactivated 
circulating alveolar macrophages, surfactant, and inspired air.   
During ALI, as shown on the right of figure 1, the barriers made by the cells of the 
microvascular endothelium and the alveolar epithelium are disrupted. Initial damage to 
the endothelial barrier leads to an increase in pro-inflammatory molecules as a direct 
result of endothelial cell damage. Barrier instability and an uptick of adhesion molecules 
along the endothelial cells increases barrier permeability, allowing circulating and 
recruited neutrophils to enter the interstitial space. Activated neutrophils further produce 
pro-inflammatory cytokines and pro-apoptotic mediators, extrapolating the recruitment 
of additional neutrophils through chemotaxis. As capillary permeability continues to 
increase, protein rich fluid floods the interstitial space. This pressure and influx of pro-
inflammatory and pro-apoptotic mediators causes barrier instability between type I and 
type II alveolar epithelial cells, allowing excess fluid into airspaces of the alveoli, 
clinically recognized as pulmonary edema (16). Interruption of the normal fluidic balance 
between the epithelial barrier prevents type II epithelial cells from pumping out edema 
flooding, broadening the existing trauma. Continued damage to type II cells causes 
dysfunction of surfactant production, staging the alveoli for a surfactant imbalance which 
may result in long-term surfactant dysregulation. Additionally, damage to the type II cells 
leads to unsystematic repair of the epithelial barrier, potentially promoting the formation 
of fibrotic tissue (17).  
Resolution of ALI is dependent on the restoration of gas exchange, requiring 
correction in the fluidic imbalance between the alveolar epithelial barrier. Though 
neutrophil depletion has been shown to be a protective strategy against ALI, the 
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condition’s development in the absence of neutrophils indicates alternative pathways to 
dangerous inflammation (18-20). Pharmacological treatments include the use of β-2 
agonists, which increase alveolar fluid transport, and the use of bone marrow-derived 
mesenchymal stem cells (MSCs), which aim to improve endothelial and epithelial barrier 
integrity.  
ALI can progress rapidly leading to pulmonary vascular destruction, pulmonary 
fibrosis, and multiple organ failure due to low oxygen levels, the culmination of which 
ultimately concludes in death. Due to the severe damage that occurs in just one episode 
of ALI, those that survive often experience long-term physical, cognitive, and mental 
adverse effects (21).    
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Figure 1. Normal alveolus (left) compared to alveolus during acute lung injury.  
When the lung endothelial barrier is disrupted, neutrophils are recruited and migrate into 
the interstitial space. Pro-inflammatory molecules cause further disruption of the 
alveolar epithelial barrier, allowing a flood of edema fluid into the alveolar space. 
Continued damage results in cell death among both epithelial and endothelial cells. 
Figure reproduced with permission from The New England Journal of Medicine (22), 
Copyright Massachusetts Medical Society. 
 
 
The pathophysiology of ALI development may differ between stimuli and has 
been shown to be an important predictor of outcome. For example, infection-onset ALI 
has a higher mortality rate than trauma-induced ALI (23). It is also known, as previously 
mentioned, that certain ailments may predispose patients to ALI development. The 
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majority of cases develop in the presence of an infection, the most common of which 
being primary pneumonia (4). Sepsis is the second most common cause, and contrary 
to pneumonia may result from a non-pulmonary associated source. Other non-
pulmonary associated sources include malaria and SCD, and though these diseases 
differ greatly, they are all associated with a high degree of intravascular hemolysis. 
Moreover, studies of sepsis have actually found that the higher the degree of 
intravascular hemolysis, the poorer the clinical outcome (24-26). Together these 
indicate a viable link between a large degree of intravascular hemolysis and the 
development of ALI.  
1.3 HEMOLYSIS, HEME, AND ALI 
The large degree of intravascular hemolysis that occurs in SCD, malaria, and 
sepsis may be a primary stimulus for ALI in patients. As demonstrated in figure 2, 
hemolysis is the rupture of red blood cells (RBCs) which allows for the release of 
hemoglobin directly into the bloodstream. Ferrous (Fe2+) hemoglobin, when free from 
the RBC, is easily oxidized to ferric (Fe3+) hemoglobin. Upon the addition of a single 
oxygen molecule, four heme molecules are released from hemoglobin. Heme is the 
oxygen binding portion of hemoglobin and holds essential functions in aerobic 
organisms including chemical catalysis and electron transfer. However, upon release 
from the hemoglobin molecule, heme becomes “free” and is toxic to the body via the 
formation of reactive oxygen species (ROS) and ability to trigger strong inflammatory 
responses. Free heme is a known danger-associated molecular pattern (DAMP), which 
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is an endogenous molecule capable of exacerbating the immune response. During 
cases of severe hemolysis, such as the aforementioned malaria, sickle cell disease, and 
sepsis, large amounts of hemoproteins are released into the circulation, thus leading to 
the release of large amounts of toxic free heme. The accumulation of this endogenous 
toxic molecule poses a problem specifically to the cells lining the blood vessels, 
including the vascular endothelium of the lung capillary-alveolar membrane.  
Figure 2. Hemolysis results in the release of free heme, designated as an 
erythroid DAMP molecule. 
Excess circulating heme can result in vascular injury through sterile inflammation, which 
may contribute to the pathogenesis of hemolytic diseases. Original figure adapted with 
permission from Blood (27). 
1.3.1 Mechanisms of Heme induced lung injury 
The connection between hemolysis and induced lung injury has been exhibited in 
numerous experimental animal models, including those of sepsis and SCD (26, 28 R 
2010). It is known that endothelial cells of the alveolar-capillary membrane are receptive 
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to heme through the pattern recognition receptor (PRR) toll-like receptor 4 (TLR4) (29). 
Endothelial cells activated by heme promote the expression of adhesion molecules such 
as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 
(VCAM-1), E-selectin, and P-selectin, aiding in the migration of neutrophils across the 
endothelial barrier (29-32). Furthermore, heme induces interleukin-8 (IL-8), an important 
chemoattractant of neutrophils and recognized bio-marker of ALI.  
Importantly, it has been established that rescue from ALI is possible through the 
use of heme-scavengers, namely hemopexin (Hx) and haptoglobin (Hp). These 
endogenous molecules exist to scavenge heme under normal physiologic 
circumstances. Hx in particular, binds heme with high affinity and transports it to the 
liver for degradation. However, these scavengers become exhausted in individuals 
suffering from severe hemolytic crisis, resulting in an amass of toxic heme throughout 
the circulation. Experimentally, it has been shown that acute exacerbation of heme 
followed by therapeutic treatment with Hx alleviates respiratory failure in a murine model 
of ALI (33). In murine models of sepsis, prophylactic treatment with Hx prevented 
mortality (26), while clinically, high Hp levels are associated with lower mortality rates in 
adults suffering from sepsis (25).  
Together these studies strongly suggest that heme and defective heme-
scavenging mechanisms is a significant contributor to the pathophysiology of ALI. 
Unfortunately targeting and replacing the Hx scavenger may have limited therapeutic 
value in patients, for though it is successful in resolving ALI, significant liver damage 
occurs (34). Therefore, additional studies to elucidate other mechanistic pathways, such 
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as intracellular inflammatory signaling pathways of the endothelial cells, are needed to 
identify new potential targeted-therapies to prevent or treat heme-induced ALI.  
1.4 TLR4 AND INFLAMMASOME ACTIVATION 
TLR4 activation is also known to induce the assembly of inflammasomes, which 
are multiprotein complexes of the innate immune response functioning to activate pro-
inflammatory molecules that lead to an inflammatory cascade. The exact composition of 
the inflammasome complex depends on the stimulus, but generally consists of a 
caspase protein, the adaptor protein apoptosis-associated speck-like protein containing 
a caspase recruitment domain (35), and either sensor protein family NOD-like or AIM-
like receptors, as displayed in figure 3. After recognition of a specific stimulus by the 
sensor protein, the adaptor protein, ASC, recruits the caspase protein (for simplicity, 
caspase-1) which is then cleaved into its active subunits p10 and p20. Once activated, 
caspase-1 can cleave immature inflammatory cytokines, pro-interleukin-18 (pro-IL-18) 
and pro-interleukin-1β (pro-IL-1β) to their active form interleukin-18 (IL-18) and 
interleukin-1β (IL-1β), which is illustrated by figure 4. Upon release on the systemic 
level, IL-1β causes fever and leukocyte migration, while IL-18 induces interferon-γ (IFNγ) 
and has been shown to have natural killer cell priming activity (36). 
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Figure 3. General inflammasome composition.  
Original picture reproduced from InvivoGen. “Inflammasomes-Review” (2012). 
www.invivogen.com
1.4.1 The NLRP3 Inflammasome 
Of the known inflammasome complexes, the nod-like receptor protein-3 
(NLRP3) is the most widely characterized and is known to be activated by a variety 
of stimuli of both endogenous and pathogenic nature. In human disease, NLRP3 has 
been found to be the cause of cryopyrin-associated periodic syndromes (CAPS) which 
are a group of recognized genetic autoinflammatory diseases (37, 38). In addition to 
CAPS, NLRP3 also has implications in gout, type-II diabetes, obesity-induced 
insulin resistance, cancer, asbestosis, and Alzheimer’s disease (39-50).   
The exact course of NLRP3 activation can be a debatable subject, as there 
seem to be a variety of mechanistic pathways that each involve multi-step signal 
activation. The two major recognized activation pathways are broken down into 
the canonical pathway and the non-canonical pathway. For the canonical pathway, 
depicted in figure 4, two step-wise signals are required for activation. First, TLR 
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stimulation, which seems to function in order to initiate the transcription of immature 
cytokines via cleavage by caspase-1. While these cell damage signals are still under 
investigation, popular signals seem to include potassium efflux (51) and ROS 
generation (52).  
The non-canonical pathway, as depicted in figure 5, is considered dependent on 
m-caspase-11 (mouse-caspase-11; human-caspase-4 and capsase-5) (53, 54), 
whereby once activated, it promotes the activation of NLRP3 and indirectly enhances 
pro-IL-18 and pro-IL-1β (35, 55-61). Pryoptosis, a highly inflammatory form of 
programmed cell death follows NLRP3 initiation of the pro-inflammatory cascade in both 
pathways. 
Figure 4. Stimulation caused by PAMP or DAMP molecules causes 
oligomerization of NLRP3 inflammasome. 
When activated, inflammasome cleave caspase-1 for activation which leads to the 
cleavage of pro-IL-18 and pro-IL-1β into mature forms prepared for release from the 
cell. Reproduced with permission from Nature Reviews Immunology (62). 
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Figure 5. Non-Canonical NLRP3 Activation. 
Intracellular stimulation of caspase-11 indirectly increases pro-IL-18 and pro-IL-1β and 
causes oligomerization of NLRP3 inflammasome. Reproduced with permission from 
Nature Medicine (63).  
What separates these two pathways is the stimulus. The non-canonical pathway 
is known to be induced by several gram-negative bacteria, but not gram-positive 
bacteria, which indicates a specific role for TLR4. Studies employing cytosolic LPS have 
been shown to activate the non-canonical pathway (57, 64), indicating an independence 
from TLR4. However, both canonical and non-canonical pathway signaling are 
increasingly being found to have an additional dependence on caspase-8 for priming 
and activation of TLR-associated stimuli (65-67). Furthermore, studies have indicated 
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that different stimuli result in a differential balance of IL-1β and IL-18 release (68, 69) 
potentially concluding in a different immune response. 
1.4.2 Heme as an Activator of NLRP3 
Several studies have shown that inflammasomes play a critical role in sepsis and 
mechanical ventilation induced ALI development (70, 71). Furthermore, inflammasome 
activation, specifically NLRP3, via heme stimulus has been reported, but only in 
combination with lipopolysaccharide (LPS) priming in macrophages (72). While we have 
previously shown that acute exacerbation of circulatory heme, in the absence of LPS, 
triggers endothelial barrier disruption and ALI in vivo (33), the exact cellular mechanism 
behind this damage remains largely unknown. The association between heme and ALI 
combined with the fact that heme functions as a DAMP molecule able to signal through 
TLR4, lends the question of possible inflammasome activation via heme.  However, 
inflammasome activation as a result of heme stimulus in the absence of LPS has not 
been studied in the context of ALI development. 
14 
2.0  STATEMENT OF THE PROJECT 
In this project, we seek to investigate the pathobiological role of free heme in 
activating the NLRP3 inflammasome within vascular endothelial cells. Inflammasome 
activation within vascular endothelial cells of the alveolar-capillary membrane would 
contribute to the inflammatory response recognized during ALI as well as the dysfunction 
of the endothelial barrier that causes ALI. We will test the overall hypothesis that 
extracellular heme induced acute lung injury is mediated by the activation of the 
endothelial NLRP3 inflammasome.  
15 
 
Figure 6. Graphical Abstract. 
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3.0  SPECIFIC AIMS 
Two Specific Aims are formulated to test this hypothesis: 
3.1 [AIM 1] DETERMINE THE ABILITY OF HEME TO INDUCE NLRP3 IN 
PULMONARY ENDOTHELIAL CELLS.  
We will confirm that heme alone will induce NLRP3 in endothelial cells by measuring 
caspase-1 activity through the expression of IL-1β and IL-18 release in human primary 
microvascular endothelial cells (HMVEC-Ls). We will also test whether activation of 
NLRP3 is associated with endothelial barrier disruption. The following methods will be 
utilized to test the stated aim: 
1. Assess impact of heme treatment on cell death and barrier stability using
cultured HMVEC-Ls. Cell death will be quantified through lactate dehydrogenase
assay, while specific barrier function will be assessed through electric-cell
substrate impedance sensing technology (ECIS).
2. Evaluate potential presence of NLRP3 inflammasome machinery by measuring
the output of IL-18 and IL-1β through ELISA.
3. Detect presence of NLRP3 inflammasome protein through western blot analysis.
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3.2 [AIM 2] DETERMINE THE IMPORTANCE OF NLRP3 DURING HEME 
INDUCED ACUTE LUNG INJURY.  
We will investigate whether NLRP3 activation is a critical component during the 
progression of heme induced acute lung injury. We will examine the effects of inhibition 
of NLRP3 in vivo, utilizing our model of heme induced ALI in transgenic sickle mice. The 
following methods will be used to fulfill the stated aim: 
1. Establish the efficacy of NLRP3 inhibition in improving barrier dysfunction and
cell death during heme treatment in HMVEC-Ls. Previously mentioned
measurements of cell death and barrier stability will be utilized to measure
potential rescue of cells during heme treatment.
2. Verify the inhibition of NLRP3 through expression of IL-18 and IL-1β via ELISA.
3. Determine efficacy of NLRP3 inhibition during in vivo heme-induced ALI.
At the end of this project, we will able to confirm whether NLRP3 is a significant 
factor in heme induced acute lung injury.  
18 
4.0  MATERIALS AND METHODS 
4.1 REAGENT PREPARATION 
4.1.1 Heme 
Hemin (Frontier Scientific, Logan, UT) was dissolved in 0.25M sodium hydroxide 
(Fisher Chemical, Pittsburgh, PA) and pH was adjusted to 7.5 with 12M hydrochloric 
acid (Fisher Scientific). The solution was adjusted to the appropriate concentration in 
cell culture media or 1xPBS (Hyclone, GE Healthcare Life Sciences, Chicago, IL) for in 
vitro or in vivo experiments respectively. When necessary, hemin was dissolved in 
DMSO (Sigma, St. Louis, MO) and again brought to the appropriate concentration using 
cell culture media or saline (Thermo Scientific). For the vehicle analog, 0.25M sodium 
hydroxide was adjusted to pH 7.5 with 12M hydrochloric acid and the appropriate 
dilution was prepared using cell culture media. 
4.1.2 MCC950 
MCC950 (InvivoGen-10mg, San Diego, CA) was dissolved in DMSO and diluted 
to the appropriate concentration in cell culture media or saline. To avoid DMSO toxicity 
in mouse experiments, total volume of MCC950 was doubled using saline. For all 
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experiments with MCC950, heme was dissolved in DMSO as previously described to 
serve as the most appropriate vehicle.  
4.2 CELL CULTURE 
 Human microvascular lung endothelial cells (HMVEC-L, Lonza, Basel, 
Switzerland) were cultured according to manufacturer’s protocols in Endothelial Cell 
Growth Medium (EBM-2, Lonza) with added supplement pack (EGM-2MV SingleQuots, 
Lonza) containing 10% fetal bovine serum. Cells were plated at 125,000 cells/well on 
six-well plates, 20,000 cells/well on ECIS arrays, and 8,000 cells/well on 96-well plates 
and allowed to grow to confluence. On day of confluence, typically 48 hours after 
plating, cells were treated with the appropriate stimulant or vehicle. All experiments 
were performed using serum-free media.   
4.2.1 Cell Lyses and Sample Collection   
 Samples were collected at pre-designated times, 3-12 hours after treatment. For 
supernatant sample collection, cell media was aspirated from cells and immediately 
frozen at -80°C until further analysis. For cell lysate sample collection, PierceTM IP Lysis 
Buffer (ThermoFisher Scientific) containing HaltTM Protease Inhibitor (ThermoFisher 
Scientific) was placed directly on cells and incubated at 4°C for 10-15 minutes on a 
rocking plate. Cells lysates were then scraped from the plate and frozen at -80° C until 
further analysis.   
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4.3 LACTATE DEHYDROGENASE (LDH) ASSAY 
HMVEC-Ls were cultured as previously described on 96-well plates. On day of 
confluence, typically 48 hours after plating, cells were stimulated with heme or 
heme+MCC950 with appropriate vehicle controls. At pre-designated times, entire 
supernatant volumes were transferred to a “collection” 96-well plate. Collection plate 
was placed in -30°C freezer in between different points of collection. After the collection 
of all samples, collection plate was brought to room temperature for quantification of 
LDH using QuantiChromTM LDH Cytotoxicity Assay Kit (BioAssay Systems, San 
Francisco, CA) according to manufacturer’s protocols.   
4.4 ELECTRIC CELL-SUBSTRATE IMPEDANCE SENSING (ECIS) 
The Electric Cell-Substrate Impedance Sensing (ECIS) system (Applied 
BioPhysics, Troy, NY) uses impedance-based technology to detect cell activity and 
movement in response different stimulants. HMVEC-Ls were cultured as previously 
described and plated at 20,000 cells/well without serum on 8W10E+ PET arrays, which 
are arrays specially fitted with electrodes. On day of confluence, typically 48 hours after 
plating, arrays were placed on the ECIS apparatus. Within the ECIS incubator, a small 
current (I) applied to the arrays causes the cells to act as insulators, resulting in a 
measurable potential energy (V) across the cell monolayer. Together, the impedance 
(Z) is quantified using Ohm’s law, where Z=V/I. Under confluent conditions with no
stimulant, the impedance remains constant. When a stimulant (for example, heme) is 
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added, or the cells are disturbed, their insulating activity decreases, corresponding to a 
decrease in impedance and decrease in resistance. For all experiments, baseline 
measurements were taken for at least two hours prior to the addition of stimulant to 
ensure consistent baseline quantities. 
 
 
4.5 IL-18 AND IL-1β (ELISA) 
 IL-18 and IL-1β ELISA kits were purchased from R&D Systems (Minneapolis, 
MN). Concentrated cell supernatant was used for detection of either IL-18 or IL-1β 
expression via ELISA to determine mature cytokine release from treated cells. Protein 
Figure 7. Electric Cell Substrate Impedance Sensing Apparatus.  
Main photo depicts culture arrays on electric platform.  
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concentration (PierceTM BCA Protein Assay Kit; ThermoFisher Scientific) was 
determined for normalization of ELISA results for all values reported as pg/mg protein.  
4.5.1 Protein Concentration 
 Cell supernatant collected from treated HMVEC-Ls was concentrated using 
Amicon Ultra-2 mL Centrifugal Filters (Millipore Sigma, Burlington, MA). Briefly, 
previously collected supernatant was placed in filter units and spun 2272 x g for 90 
minutes at 4° C. Filter units were then reversed and re-spun at 2200 x g for 10 minutes 
at 4° C, allowing for the concentrate to collect at the bottom of the collection tube. Filters 
were rinsed with 20 µl cold 1xPBS and spun for an additional 15 minutes at 2200 x g to 
ensure proper rinse of filters.  
4.6 WESTERN BLOT ANALYSIS 
 Cell lysates of HMVEC-Ls treated with heme were concentrated using Amicon 
Ultra-0.5mL Centrifugal Filter units (Millipore Sigma). Protein concentration was 
determined using PierceTM BCA Protein Assay Kit (ThermoFisher Scientific). Samples 
were placed in 4x laemeli sample buffer (BioRad, Hercules, CA) and diluted in 
nuclease-free water to equilibrate all protein levels prior to heating at 95°C for five 
minutes. Equal amounts of protein were then separated on pre-cast 7.5% TGX gel 
(BioRad). Protein was transferred to nitrocellulose membrane (BioRad) and blocked for 
two hours in 5% milk in TBST (BioRad). Blots were then probed for NLRP3 (Cell 
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Signaling, Danvers, MA, 1:5000) with the secondary antibody anti-rabbit (Vector, 
Burlingame, CA, 1:5000). Alpha-tubulin (Abcam, Cambridge, UK, 1:10000) was used for 
the loading control, with the secondary antibody anti-mouse (Vector, 1:10000). 
4.7 HEME INDUCED ALI IN MICE 
Transgenic Townes’ sickle mice (73) expressing exclusively human sickle 
hemoglobin (SS) and hemizygous (AS) age-matched controls were used for animal 
studies. All animal procedures were approved by the Institutional Animal Care and Use 
Committee of the University of Pittsburgh (IACUC).  
4.7.1 Physiological Measurement of Pulmonary Hypoxemia 
Mice, 10-12 weeks of age were anaesthetized using isoflurane and shaved 
around the collar using NairTM Hair Remover Cool Gel (Church & Dwight CO, Inc. 
Ewing, NJ) 48 hours prior to experimental procedure. On day of procedure, mice were 
again anaesthetized using isoflurane (Henry Schein, Melville, NY) and attached to a 
mouse-adapted pulse-oximeter (Mouse-Ox Plus, Starr Life Sciences, Oakmont, PA). 
Mice were then monitored to obtain baseline measurements and subsequently injected 
with freshly prepared solutions of Saline+MCC950 (i.p.), to which Saline+DMSO (i.p.) 
served as the vehicle, and heme (70 µmoles/kg, i.v.). Mice were monitored for up to two 
hours or until oxygen saturation levels dropped below 85% for a continuous period of 
five minutes. Mice were then sacrificed using a CO2 chamber. 
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Figure 8. Mouse-Ox Plus Pulse-Oximeter.  
Image of awake mouse attached to Mouse-Ox Plus apparatus and corresponding 
output of respiratory measurements.   
4.7.2 Pulmonary Edema  
 Gravimetric analysis of the large left lobe of the mouse lung was used as a 
measure of pulmonary edema. Immediately after death, the left lung lobe was harvested 
and weighed using an isometric transducer (Harvard Apparatus, Holliston, MA). Lungs 
25 
were then dried in an oven containing desiccant crystals at 80°C for 48 hours. Dry 
weight was then determined in the same manor and wet/dry ratios were calculated.  
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5.0  RESULTS 
5.1 [AIM 1] DETERMINE THE ABILITY OF HEME TO INDUCE NLRP3 IN 
PULMONARY ENDOTHELIAL CELLS.  
5.1.1 Heme is cytotoxic and causes barrier disruption among human 
microvascular endothelial cells  
Human microvascular endothelial cells (HMVEC-Ls) were cultured to form a 
confluent monolayer. Using release of intracellular lactate dehydrogenase (LDH) as a 
measure of cell death, cells challenged with heme (10 μM) showed a 75% increase in 
cytotoxicity at three hours post treatment as compared to vehicle controls (figure 9A). 
This cytotoxicity decreased at six hours, indicating slight recovery, but increased again 
up to 100% at 12 hours post treatment. This indicates that heme is toxic to endothelial 
cells and capable of inducing a large degree of endothelial cell death.  
Loss of vascular barrier integrity is a characteristic feature of ALI. Therefore, we 
tested whether heme induced cell death is associated with the disruption of cell-to-cell 
contacts within a monolayer of HMVEC-Ls. Using ECIS technology, heme treatment 
was found to cause significant barrier disruption among a confluent monolayer of 
HMVEC-Ls (figure 9B-D). Figure 9B is a representative graph displaying the typically 
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observed drop in normalized resistance as a result of heme stimulation. Thrombin, 
known to cause endothelial barrier disruption, is used as a positive control (74-76), and 
shows a slight recovery of barrier integrity over time, while heme challenge failed to 
show any recovery (figure 9C,D). 
Taken together, these data demonstrate endothelial barrier disruption as a result 
of cell death due to heme stimulation. As a DAMP molecule, heme may trigger multiple 
intracellular antecedent events including inflammasome activation that eventually leads 
to cell death.  
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Figure 9. Heme causes cytotoxicity and endothelial barrier disruption in HMVEC-
Ls. 
(A) Percent cytotoxicity quantified via LDH release as compared to vehicle at 3, 6, and 
12 hours post 10 µM heme challenge. Data represented as a mean±SEM of three 
separate experiments (n=3). (B) ECIS output of HMVEC-Ls treated with 10 µM heme. 
Output displays up to three hours post heme challenge. Apparent recovery of thrombin 
treated cells is evident via gradual rise in normalized resistance (red and light blue 
lines). (C, D) Corresponding percent resistance drops in heme and thrombin challenged 
wells at 30 minutes and 3-hours (p=0.048) post heme and thrombin addition. Data 
represents results of two separate experiments. All data normalized to vehicle.  
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5.1.2 Heme induces IL-1β and IL-18 secretion from HMVEC-Ls 
Activation of NLRP3 inflammasomes results in the induction of caspase-1, which 
in turn cleaves pro-inflammatory cytokines Pro-IL-18 and Pro-IL-1β. They are then 
released from the cell in their mature form of IL-18 and IL-1β.  Therefore, in order to 
determine the possible induction of NLRP3, supernatant from HMVEC-Ls treated with 
heme (10 μM) was collected and subsequently analyzed for the presence of IL-18 and 
IL-1β. We consistently observed a significant increase in IL-18 at the three-hour 
(p=0.046, n=4) and 12-hour (p=0.0024) time points post treatment (figure 10A). These 
results align with the time points of highest cytotoxicity observed in figure 9A. Though 
increases in IL-1β (pg/mL) were not found to be significant (figure 10B) we did observe 
up to a 25% increase in IL-1β (n=4, figure 10D) compared to vehicle when displayed in 
this manner.  
The increased expression of both IL-18 and IL-1β indicates the induction of 
cytokine processing machinery as a result of heme challenge. Because activation of 
NLRP3 occurs upstream of the cellular events required for IL-18 and IL-1β release, we 
have evidence for finding NLRP3 expression in heme treated endothelial cells.  
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Figure 10. IL-18 and IL-1β expression after heme treatment. 
(A) IL-18 release expressed as pg/mg protein significantly increases at three (p=0.046)
and 12 hours (p=0.0024) post heme challenge. Data represents four separate
experiments (n=4). (B) IL-1β expressed as total pg/mL, results represent  four separate
experiments (n=4). (C, D) Fold change in IL-18 (*p=0.046, **p=0.0024) and IL-1β
expression as compared to vehicle at each respective time point.
Differential NLRP3 expression is apparent in HMVEC-Ls treated with heme 
Western blot analysis reveals a slight difference in NLRP3 expression, most 
notably at three hours post treatment with 10 μM heme (figure 11). Alpha-tubulin used 
as the house keeping protein reveals unequal protein loading, however, because the 
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loading appears consistent within the indicated time points (excluding 12 hour), it is 
apparent that an increase in NLRP3 protein expression occurred after 3 hours of heme 
challenge. This is preliminary data and requires confirmation. Nonetheless, this data 
further supports the significant increase in extracellular IL-18 (Figure 10) and indicates 
that heme stimulates NLRP3 activity within endothelial cells.  
Figure 11. Western Blot of NLRP3. 
Top panel NLRP3, bottom panel house-keeping alpha-tubulin. Total protein was 
quantified using BCA protein assay. Whole cell lysates of HMVEC-Ls, with 15 μg protein 
loaded in each lane.  
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5.2 [AIM 2] DETERMINE THE IMPORTANCE OF NLRP3 DURING HEME 
INDUCED ACUTE LUNG INJURY.  
5.2.1 Inhibition of NLRP3 with MCC950 does not attenuate cell death in heme-
treated HMVEC-Ls  
MCC950 is a selective inhibitor of NLRP3, known to prevent its activation without 
interfering with the activation of other inflammasomes or TLR4 signaling (77). As a 
consequence of MCC950 treatment, studies have reported a decrease in IL-1β 
production (77, 78). In order to determine whether NLRP3 inhibition would alleviate 
some of the cytotoxic effects of heme, we again measured the amount of LDH in 
cultured HMVEC-Ls that were simultaneously treated with heme (10 µM) and MCC950 
(50-100 µM) (figure 12). The combination of two experiments indicated a significant 
increase in cytotoxicity as a result of both 50µM (p=0.0008) and 100µM (p=0.0422) 
MCC950 treatment at three-hours of treatment, when compared to vehicle. However, 
visual analysis of the cells at this time point did not correlate to the supposed 100% 
death that the LDH analysis suggests. Furthermore, the six, and 12-hour time points 
indicate no significant change in cytotoxicity. 
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Figure 12. Cytotoxicity with MCC950. 
Percent cytotoxicity quantified via LDH release in HMVEC-Ls treated with 10 µM heme. 
Significant increase with 50µM (p=0.0008) 100µM (p=0.0422) MCC950 observed at 
three hours of treatment. Data result of two separate experiments.  
5.2.2  MCC950 attenuates barrier disruption in HMVEC-Ls treated with heme 
Though we did not observe an overall rescue of cells based on the LDH 
cytotoxicity assay, we did observe attenuation of the endothelial barrier disruption 30 
minutes and three hours after 10 µM heme treatment (figure 13A,B). Figure 13C is a 
representative graph displaying the slight rescue of barrier integrity with 50 µM 
MCC950, as a gradual increase in normalized resistance is observed between 3-4.5 
hours. This rescue continues throughout three hours, following the trend of the vehicle 
treated cells. This indicates that there is some potential salvaging quality to NLRP3 
inhibition via MCC950.  
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Figure 13. Barrier integrity is increased with NLRP3 inhibition via MCC950.
All data represents three separate experiments, and all treatment conditions are 
normalized to vehicle. (A) Percent normalized resistance 30 minutes after heme, 
heme+MCC950, or vehicle addition. (B) Percent normalized resistance 3-hours 
after heme, heme+MCC950, or vehicle addition. (C) Representative graph of 
normalized resistance up to two hours post heme addition. Gradual recovery of 
MCC950 treated cells is observed by the slight rise in normalized resistance (green 
and yellow lines). 
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5.2.3 Different doses of MCC950 has varying effects on IL-18 and IL-1β release 
from HMVEC-Ls treated with heme 
In order to determine whether the doses and treatment regimen of MCC950 were 
able to inhibit the processing of IL-18 and IL-1β, supernatant from HMVEC-Ls that were 
simultaneously treated with both heme and MCC950 was collected and analyzed for 
the two analytes using ELISA. When compared to vehicle, we observed a significant 
increase in IL-18 (p=0.008) with sole heme treatment, as well as a significant increase 
with 10 µM (p=0.0191) and 100 µM (p=0.0072) MCC950+heme treatment (figure 
14A,C). However, no significant change in IL-18 release was noted between the heme
+50 µM MCC950 dose and vehicle (figure 14A,C). Furthermore, an apparent but not
significant decrease in IL-18 is noted between heme and heme+50 µM MCC950 (figure 
14A,C).  This indicates that the 50 µM dose of MCC950 has potential of inhibiting IL-18 
processing in HMVEC-Ls treated with heme (50 µM).  We also observed a non-
significant decrease in IL-1β with the 50 µM MCC950 dose (figure 14B,D). Further dose 
optimization is needed in order to indicate whether MCC950 is able to completely 
reduce cytokine levels to baseline or vehicle expression. If dose optimization does not 
result in significantly reduced cytokine levels, we can conclude that other mechanistic 
pathways aside from NLRP3 are responsible for IL-18 and IL-1β release.  
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Figure 14. IL-18 and IL-1β release after heme+MCC950 addition.  
(A) Release of IL-18 expressed in total pg/mL after 6-hours of 10 µM heme+MCC950 
treatment. Significant increase in IL-18 with heme (p=0.008), heme+10µM MCC950 
(0.0191), and heme+100µM MCC950 (p=0.0072). All data represents two separate 
experiments. (B) Release of IL-1β in cell supernatant expressed in total pg/mL after 6-
hours of 10 µM heme+MCC950 treatment. All data represents two separate 
experiments. (C-D) Fold change of IL-18 and IL-1β expression compare to vehicle. 
Significant increase in IL-18 with heme (p=0.008), heme+10µM MCC950 (p=0.0191), 
and heme+100µM MCC950 (p=0.0072). 
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5.2.4 Prophylactic treatment with MCC950 is unable to prevent mortality in a 
murine model of ALI 
Because of the previously observed preventative qualities of MCC950 in barrier 
disruption and, though weak, inhibition of pro-inflammatory cytokine release, we 
questioned whether there was potential for condition attenuation during our murine 
model of ALI. As described in the Methods, mice (10-12wk) were attached to a mouse-
adapted pulse-oximeter and injected with MCC950+Saline (i.p., 25µg/g) (77) or 
DMSO+Saline (i.p.) (figure 15A). One vehicle mouse expired prior to the injection of 
heme via tail vein, while the remaining were monitored for one hour before infusing 70 
µmoles/kg heme (i.v.) to induce ALI (figure 15A,B). All mice experienced a sudden and 
severe drop in oxygen saturation (figure 15D), a characteristic of acute lung injury, and 
expired prior to an hour and 30 minutes after heme injection (figure 15B). 
Though NLRP3 inhibition had no effect on mortality, it did appear to have an 
effect on the lung wet-to-dry weight ratio, as MCC950 treated mice displayed a 20% 
decrease (figure 15C), indicating vehicle mice suffered more severe pulmonary edema 
than MCC950 treated mice. Ultimately, this implies a decrease in overall vascular 
leakage, which does corroborate previous findings of increased barrier integrity from the 
ECIS. However, great caution is taken in interpreting these results, as only two vehicle 
mice survived long enough to gate the measurement. Repeated cohorts are needed to 
confirm results.  
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Figure 15. MCC950 prophylaxis in a murine model of ALI. 
(A) Experimental design. (B) Survival curve including survival control (AS mouse) which
did not succumb prior to two hours. n=7 total, MCC950 n=3, Vehicle n=3, AS control
n=1. (C) Wet-to-dry weight ratio of MCC950 treated mice compared to vehicle treated
mice. MCC950 n=3, Vehicle n=2 (D-G) Real time physiological measurement of (D)
percent oxygen saturation, (E) breath rate, (F) heart rate, and (G) pulse distention
during baseline, MCC950 prophylaxis, and after heme infusion. MCC950 n=3, Vehicle
n=3
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6.0  DISCUSSION 
The onset of ALI stems primarily from the disruption of the lung endothelial 
barrier. Heme, well-known as a DAMP molecule, is increased in patients suffering from 
several forms of hemolytic crisis, all of whom are placed at an increased risk of 
developing ALI (4, 23). Portions of this study exhibit the damaging effects that heme can 
cause on lung endothelial cells, supporting the theory of heme-induced ALI. However, 
the exact cellular mechanism underlying how heme stimulates endothelial cell damage 
that may propagate barrier disintegration is largely unknown. Previous reports of heme-
induced inflammasome activation within monocytes initiated the speculation as to 
whether the inflammatory effects caused by heme are occurring through the activation 
of inflammasomes (72, 79). The NLRP3 inflammasome specifically is known to be 
activated by a variety of stimuli, including those of endogenous nature, making it a 
prime candidate for primary investigation (72, 79-81). Therefore, the goal of this project 
was to determine whether heme is able to induce NLRP3 inflammasome activation 
within endothelial cells. If true, this would likely be a major component in the onset of 
ALI that could be targeted through therapeutic agents.  
In order to determine the potential activation of NLRP3, it was foremost 
necessary to quantitate the damage heme causes to lung endothelial cells. Using 
HMVEC-Ls, cell death was found to be consistently increased across all time points 
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compared to vehicle in three separate experiments, exhibiting 75% cell death after three 
hours of treatment. This death corresponded to a 75% decrease in barrier resistance 
measured through ECIS, physiologically translating to severe cell-to-cell breakage 
throughout the endothelial cell barrier ultimately resulting in vascular leakage.  
This observed cell death and endothelial barrier disruption reveals that heme is 
able to trigger a large degree of cell stress responses. In order to determine whether 
this stress was related to inflammasome activation, subsequent analysis for the 
presence of IL-18 and IL-1β was performed. The maturation of both cytokines is known 
to be largely reliant on the activation of caspase-1, which must first be cleaved to its 
active form by the NLRP3 inflammasome upstream in the sequence of cellular events 
(See figure 4,5). Therefore, the analysis of supernatant taken from HMVEC-Ls treated 
with heme was used as a primary step in determining whether there was a possibility of 
NLRP3 activation. Supernatant taken directly from the HMVEC-Ls showed an elevation 
of both IL-18 and IL-1β, confirming an increase of extracellular release for both 
cytokines compared to vehicle treated cells.  
Though the rise in both cytokine levels is a compelling factor in support of the 
overall hypothesis, alternative cytokine maturation pathways are possible. Therefore, it 
was further necessary to detect actual protein levels of NLRP3 within the endothelial 
cells. Through western blot analysis, an apparent increase in NLRP3 expression in 
HMVEC-Ls can be observed at three hours post treatment. This increase in expression 
aligns with the increased release of IL-18 and IL-1β, indicating a prominent role of 
NLRP3 in the maturation and release of these cytokines.  
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After determining a conceivable link between the amplified release of IL-18 and 
IL-1β and the activation of NLRP3, it was vital to proceed with experiments using an 
NLRP3 inhibitor, MCC950. The specific inhibition of NLRP3 via MCC950 has been 
shown in multiple publications and was desirable for use in these experiments 
particularly because of its previous use in in-vivo experimentation (77, 82, 83). The 
purpose of experiments utilizing MCC950 proved to be two-fold. First, it helped clarify 
the relationship between cytokine release and NLRP3. Second, it aided in establishing 
whether inhibition of NLRP3 resulted in an improvement of the negative heme-induced 
conditions. Though initial cytotoxicity experiments with MCC950 were not overall 
promising, I believe much of the observed cytotoxicity to be culprit of the solvent rather 
than a direct result of MCC950 treatment. Subsequent experiments investigating the 
use of DMSO as a heme solvent as compared to sodium hydroxide revealed an 
increase in overall cytotoxicity among the prior group (data not shown). Therefore, upon 
continuation of experiments using MCC950, heme was also dissolved in DMSO to 
better equilibrate DMSO concentrations between treatment conditions. With this 
correction, ECIS experiments continuously showed an improvement in barrier 
dysfunction with 50 µM MCC950 use.  
The increased barrier integrity displayed through the ECIS experiments seemed 
promising and poised the question of whether NLRP3 inhibition could be a potential 
therapeutic target in an in-vivo model of ALI. The large concentration of DMSO was a 
considerable concern for animal experiments, however, because manufacturer’s 
protocols called for the dilution of MCC950 only in DMSO, experiments proceeded 
accordingly. In an attempt to circumvent the possible toxicity of DMSO within the 
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animals, the total volume of injected amount was doubled with sterile saline. 
Furthermore, in order to determine whether DMSO toxicity was a legitimate problem 
within the experimental design, one mouse was injected with only saline. For all animal 
experiments we used transgenic homozygous sickle (SS) mice or hemizygous sickle 
(AS) mice. Our sickle mice at baseline levels experience an increased degree of 
intravascular hemolysis. During adulthood, their Hx levels have substantially decreased, 
rendering them particularly sensitive to ALI development (84). The ALI model in use 
requires a 70 µmol/kg body weight injection of heme for full ALI symptoms. The use of 
these mice more accurately mimics human disease particularly because of their lifetime 
in existence with the complications of SCD. By the time of adulthood, the mice typically 
develop noticeable multi-organ damage (33), making them a suitable substitute for what 
occurs clinically in patients.  
As suspected, all mice injected with DMSO+Saline and MCC950+Saline showed 
signs of slight distress after i.p. drug administration, while the single mouse injected 
solely with saline showed minimal signs of pain. This indicates that DMSO is 
responsible for any observed toxicity, and the increase in total volume injected and 
MCC950 were not. Unfortunately, one vehicle mouse did succumb prior to heme 
injection, however I would like to emphasize that due to the nature and sensitivity of 
these mice, sudden mortality due to stressors such as drug injection and location 
movement are not completely uncommon. Other than this mouse, all other mice 
retained consistent oxygen saturation levels, indicating no mice were in respiratory 
distress prior to heme injection. While some decrease in pulse distention does seem to 
occur after MCC950 pretreatment, both breath rates and heart rates maintained 
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expected levels. After heme treatment, all mice experienced a rapid drop in oxygen 
saturation, revealing severe and sudden respiratory distress indicative of ALI. These 
problems continued until death as some mice made slight oxygen saturation recovery, 
but none returned to baseline levels. This is a noted characteristic of our ALI model.  
 While MCC950 treatment was unable to have any effect on survival, a 20% 
decrease in the wet-to-dry lung weight ratio was observed. The wet-to-dry ratio is a 
measurement of pulmonary edema whereby an increase in the ratio specifies a greater 
severity in vascular leakage. Theoretically if in-line with my hypothesis, the observed 
decrease indicates that MCC950 was able to inhibit NLRP3 activation which foremost 
resulted in a decrease in pro-inflammatory cytokine activity and lessened endothelial 
barrier breakage. Overall, this would lead to a decrease in total cell death and 
inflammation. These results are particularly promising because they corroborate with 
the previous finding that MCC950 treatment did result in some increase in endothelial 
barrier integrity after heme treatment.  
6.1 IMPLICATIONS 
 This project demonstrates that sole heme treatment causes devastating effects 
to the lung endothelial barrier, which likely contributes to the development of ALI. 
Evidence of NLRP3 activation in response to heme was found via the increase in IL-18 
and IL-1β and furthermore through the apparent increase in NLRP3 protein levels. 
Though inhibition of NLRP3 via MCC950 failed to reduce cytokine expression to 
baseline levels and displayed no decrease in overall cytotoxicity, this could be culprit of 
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the lack of a standardized treatment protocol. The non-significant decrease in 
expression of both cytokines, the increase in barrier integrity, and the reduced wet-to-
dry lung weight ratio as a result of MCC950 treatment is promising in that it indicates 
inhibition of NLRP3 has some kind of positive effect in battling heme induced damage of 
the endothelial barrier. When applied on a physiologic level, this translates to a 
decrease in the severity of vascular permeability during an episode of ALI.  
When applying these findings on a broad level, it is important to again consider 
the mechanism of NLRP3 activation. As previously discussed, NLRP3 activation can 
occur as a result to a broad range of stimuli, and furthermore through a variety of 
pathways. Initially, this is one of the reasons NLRP3 seemed like a reasonable target for 
study-its response to many stimuli including those of endogenous nature, such as 
heme. Because NLRP3 can react to such an extensive group of stimulants, it has 
additionally been speculated as to whether or not NLRP3 actually recognizes specific 
activating motifs of differing stimuli, or whether the inflammasome responds to general 
cell homeostasis disturbances (85). While this goes along with the “cell damage” 
second signal needed for canonical activation, it does not fully explain the initial TLR-
associated signal.  
Considering heme is known to signal through TLR4, but also considering the 
possible transporter influx of heme allows for the postulation of how the non-canonical 
and canonical pathway may work together for overall activation (86). Though the 
pathways are considered independent, m-caspase-11 (human caspase-4 -5) is able to 
enhance the processing capability of caspase-1 in the presence of certain stimuli (ex. 
Cholera toxin, E. coli) (55, 87). Therefore, in considering diseases such as sepsis, the 
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prospect of an enhanced or even subdued signal resulting from the combination of 
multiple stimuli is distinctly possible. For example, a study by Li, H. et al (88) showed 
that the induction of heme-oxygenase-1 (HO-1) actually attenuated NLRP3 activation 
induced by LPS in gingival epithelial cells. What is most interesting is that the authors 
induced HO-1 by using heme (20 µM/L). Though this higher dose instigates question as 
to whether this decrease in expression was due to an increase in cell death, it could 
very well be an indicator of how variable the response to heme can be between different 
cell types, and also of the importance of heme balance within the cell. Furthermore, 
recent data from our own lab have indicated that heme also activates NLRP3 
inflammasomes in human renal proximal tubular epithelial cells (HK-2) treated with 
heme, which also results in IL-18 and IL-1β release. Together these additional studies 
support the finding of NLRP3 activation within lung endothelial cells, and further indicate 
the need to tease out specific mechanisms of activation as well as the differential 
outcomes of activation.  
The concept of heme-induced NLRP3 activation in endothelial cells is to our 
knowledge novel. Furthermore, the concept of NLRP3 induction by heme without the 
priming of LPS has not been shown. Though these results need validation, there is at 
the very least additional evidence for NLRP3 induction within endothelial cells in 
response to heme treatment.  
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6.2 AREAS OF DISCUSSION 
Of note for discussion are the previously mentioned loading concerns in figure 
11, the possible discrepancy in band identification in figure 11, the use of DMSO 
throughout the study, and the loss of a vehicle mouse prior to heme challenge which 
resulted in an n=2 in figure 15C. In considering figure 11, regardless of protein 
normalization between samples, there are apparent loading differences throughout the 
blot. However, loading between samples of the same time point seems to be consistent, 
excluding the 12 hour which was not considered for analysis. Additional concerns within 
the same figure include the identification of the correct band and the presence of 
multiple bands through the entire blot. The specified size of NLRP3 is 110kDa. As seen 
on the blot, two bands appear between the 100kDa and 150kDa markers. While the top 
band is more prominent, it seems to consistently run closer to 125kDa, while the bottom 
band runs consistently at 100kDa. A clear positive control is needed to amend this 
discrepancy, and ideally, a clear and evenly loaded repeat blot is also needed for full 
confirmation of the experiment.  
The use of DMSO throughout the cell and animal experiments did appear to have 
an effect on the overall cytotoxicity of the cells and mortality of the animals. Attempts to 
correct this were made and appeared to correct differences within the in-vitro results, 
but it is difficult to fully interpret in-vivo challenges. Therefore, the use of a different 
solvent is crucial for full confirmation of these experiments. Also, as previously 
mentioned, the results of the wet-to-dry weight ratio should be interpreted with caution, 
as one vehicle did succumb prior to heme stimulation. Unfortunately, because of time 
and availability of reagent constraint, these experiments could not be repeated.  
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One point to additionally consider is whether NLRP3 activation is directly in 
response to heme or in response to the death of surrounding cells. For example, 
adenosine triphosphate (ATP) is known to be released from cells in result to sterile 
injury and has also been characterized as an NLRP3 activator (89-91). Therefore, it is 
possible that heme is causing cell death, which results in the release of ATP (or other 
NLRP3 activators), which in turn activates NLRP3 within neighboring cells. This would 
result in an overall increase in all of the previously identified factors. Although it could be 
argued that heme is still ultimately causing the cascade, it technically would not be the 
only mediator of NLRP3 activation. This discrepancy could be solved through 
intracellular staining, or somehow interfering with ATP release from dead cells.  
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7.0  FUTURE DIRECTIONS 
Based on the performed experiments, and knowing TLR4 is a receptor for heme, 
it is easy to assume that heme acts through TLR4 to induce the canonical pathway of 
NLRP3 activation in lung endothelial cells. For verification of this speculation, it is 
foremost necessary confirm induction of NLRP3 protein and perform further protein 
analysis for caspase-1 and caspase-11 (human caspase-4 -5). This could help 
differentiate the canonical versus non-canonical pathway, further identifying the 
mechanistic routes of heme induced inflammation and also shedding light on both 
NLRP3 pathways. Furthermore, characterizing the role of TLR4 through the use of 
TLR4 inhibitors such as TAK-242 will help in distinguishing between pathways (92). In 
this study, we did not address the effect NLRP3 may have on junctional dysfunction 
between endothelial cells. Future studies aimed at identifying whether junctional 
disruption or cell death is primarily responsible for a decrease in barrier integrity would 
aid in developing targeted therapeutics.  
It is important to dissect out the specific intermediate intracellular steps within the 
NLRP3 pathway that is responsible for the inflammatory outcome of heme induced 
damage. This can be achieved by performing gain-of-function and loss-of-function 
experiments for the various previously-identified intermediates that include TLR4, 
NLRP3 and Caspase-1. In vitro experiments using siRNAs to knock-down specific gene 
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expression will confirm gene involvement. This set of experiments can be additionally 
corroborated with gene over-expression (using cDNA or viral transfection) to potentiate 
the role of TLR4, NLRP3 or Caspase-1 in endothelial cell response to extracellular 
heme. Similar in vivo experiments evaluating the effect of heme induced lung injury 
using specific gene knockout mice (for example, NLRP3-/-, Caspase-1-/- mice) will 
highlight the precise gene that can be targeted therapeutically to protect from ALI. 
Though we have shown that heme causes extensive damage to lung 
endothelium, the exact contribution of heme to the induction of ALI is likely co-
dependent on the stimulus that initiated the increase in free heme (bacterial sepsis, 
genetics, etc.). When considering the addition of any infectious agent or other DAMP on 
top of the already prominent hemolysis, there is a possibility for greater amplification of 
inflammatory response resulting in a different mechanistic route of response. IL-18 and 
IL-1β release appeared to be only partially lessened with NLRP3 inhibition, thus calling 
for the assumption that there are other cellular mechanisms responsible for their 
maturation and release. Therefore, an interesting area for future study will be the 
combinatorial effects of heme and other stimuli on NLRP3 expression. Experiments 
should focus on how the combination of different stimuli affects NLRP3 expression, and 
also how the quantified release of IL-18 and IL-1β may differ between stimuli. If 
identified, this differential cytokine expression would have major implications in how the 
body ultimately is responding to stimuli.  
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8.0  PUBLIC HEALTH SIGNIFICANCE 
As a condition that is the potential result of multiple diseases, ALI research is of 
great public health concern, both on a national and global level. This study was primarily 
focused on the ability of heme to effectively induce NLRP3 inflammasome formation 
within endothelial cells, with the ultimate goal of defining a mechanism for heme-
induced acute lung injury (ALI). Research in to the cellular mechanisms of ALI are not 
only applicable to the stimuli (which could be of infectious, genetic, or injury-onset 
nature) which cause ALI, but also potentially to those that cause the pathogenesis of 
acute respiratory distress syndrome (93). Additionally, this work sheds light on other 
aspects of endothelial barrier dysfunction induced by heme, which open up doors to the 
heme-induced damage of other cell types. As diseases associated with vasculature 
disruption and dysfunction become more common, any insight into how these cells react 
to stimuli is of benefit. Furthermore, the potential therapeutic aspect of NLRP3 inhibition 
in rescue of pulmonary edema as a result of ALI has clinical significance for the ultimate 
goal of improving patient outcome.  
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